Inicio › Linfoma de Burkitt › Massachusetts
Ensayos clínicos de Linfoma de Burkitt en Massachusetts
8 estudios sobre Linfoma de Burkitt buscan participantes en Massachusetts.
Ciudades en Massachusetts
Texto oficial del estudio (inglés)
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
ReclutandoFase 1/2
6 Months – 25 Years · Todos los sexos · Actualizado el 30 oct 2026 · NCT06395103Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
ReclutandoFase 2
365 Days · Todos los sexos · Actualizado el 27 oct 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
ReclutandoFase 2
366 Days – 46 Years · Todos los sexos · Actualizado el 27 oct 2026 · NCT06124157Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- y 1 más
ReclutandoFase 3
365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2025 · NCT03595917The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Floating Hospital for Children at Tufts Medical Center, Boston
- Dana Faber Cancer Institute/ Boston Children's Hospital, Boston
ReclutandoFase 2
Edades de 1 a 25 · Todos los sexos · Actualizado el 4 may 2025 · NCT03509961De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.